ETIOLOGY, CLINICAL STAGING AND EVIDENCE-BASED TREATMENT APPROACHES FOR PSORIASIS
Keywords:
psoriasis, plaque psoriasis, immune-mediated inflammation, PASI, topical therapyAbstract
Psoriasis is a chronic immune-mediated inflammatory skin disease with systemic implications. It is no longer interpreted only as a cosmetic disorder or a simple disturbance of keratinization; contemporary dermatology defines it as a complex inflammatory condition in which genetic predisposition, environmental triggers, dysregulated innate and adaptive immunity, and metabolic comorbidity interact. The methodological basis of the article is a narrative synthesis of dermatology textbooks used in Uzbekistan and current international guidance from dermatology organizations and public health institutions. The results show that plaque psoriasis remains the most common clinical phenotype, but scalp, nail, inverse, guttate, pustular and erythrodermic variants require differentiated clinical thinking. Severity assessment should not rely only on the visible area of lesions; special-site involvement, pruritus, pain, quality-of-life impairment and symptoms of psoriatic arthritis must also be considered. Treatment follows a stepwise model: topical therapy for limited disease, phototherapy for more extensive or resistant cases, and systemic or biologic therapy for moderate-to-severe disease or functionally disabling involvement. The article concludes that effective psoriasis management requires early recognition, careful staging, comorbidity screening and patient-centered long-term control rather than short-term suppression of plaques alone
References
1. World Health Organization. Global Report on Psoriasis. Geneva: World Health Organization, 2016.
2. National Institute for Health and Care Excellence. Psoriasis: Assessment and Management. Clinical guideline CG153. London: NICE, last reviewed 2025.
3. American Academy of Dermatology. Psoriasis Clinical Guideline: Topical Therapy, Severity Assessment and Management Recommendations. Rosemont: AAD, current online guideline.
4. European Dermatology Forum and EuroGuiDerm. Guideline for the Systemic Treatment of Psoriasis Vulgaris. Updated edition, 2025.
5. Vaisov A.Sh. Skin and Venereal Diseases. Translated title from Uzbek: Teri va tanosil kasalliklari. Tashkent: Yangi Asr Avlodi, 2009.
6. Arifov S.S., Eshboyev E. Skin and Venereal Diseases. Translated title from Uzbek: Teri va tanosil kasalliklari. Tashkent, 1997.
7. Arifov S.S. Skin and Venereal Diseases. Translated title from Uzbek: Teri va tanosil kasalliklari. Tashkent, 2010.
8. Arifov S.S. Psoriasis. Translated title from Uzbek: Psoriaz. Tashkent, 2019.
9. Djumayeva M.K., Haydarova H.A., Naimova Sh.N. Causes and Treatment Methods of Psoriasis. Translated title from Uzbek: Psoriaz kasalligining kelib chiqish sabablari va davolash usullari. Education, Science and Innovative Ideas in the World, 2024.
10. Boehncke W.H., Schon M.P. Psoriasis. The Lancet, 2015.
11. Armstrong A.W., Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA, 2020.
12. Rendon A., Schakel K. Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences, 2019.
13. Menter A., Strober B.E., Kaplan D.H. et al. Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Biologics. Journal of the American Academy of Dermatology, 2019.
14. Menter A., Gelfand J.M., Connor C. et al. Joint AAD-NPF Guidelines of Care for the Management of Psoriasis with Phototherapy and Systemic Nonbiologic Agents. Journal of the American Academy of Dermatology, 2020
15. Elmets C.A., Korman N.J., Prater E.F. et al. Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Topical Therapy. Journal of the American Academy of Dermatology, 2021.
16. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. New England Journal of Medicine, 2009